Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.
Rachel N. Grisham, MD
Advertisement
Rachel N. Grisham, MD, is an associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York
Articles by Rachel N. Grisham, MD
Rachel N. Grisham, MD, discusses efficacy and tolerability data from the phase 2 ENGOT-OV60/GOG-3052/RAMP 201 subgroup analysis.
Rachel N. Grisham, MD, discusses the safety of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.
Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.
Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.
Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.
Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.
Rachel N. Grisham, MD, discusses the mechanism of action of VS-6766 in patients with recurrent low-grade serous ovarian cancer.
Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses MEK inhibition in the treatment of patients with low-grade serous ovarian cancer.
Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses frontline treatment options for patients with low-grade serous ovarian cancer.
Advertisement
Latest Updated Articles
Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric CancerPublished: March 16th 2025 | Updated:
Dr Grisham on the Efficacy/Tolerability of Avutometinib Plus Defactinib in KRAS+ Serous Ovarian CancerPublished: April 10th 2025 | Updated:
Dr. Grisham on Frontline Treatment for Low-Grade Serous Ovarian CancerPublished: February 5th 2019 | Updated:
Dr. Grisham on MEK Inhibition in Low-Grade Serous Ovarian CancerPublished: February 27th 2019 | Updated:
Dr. Grisham on the Mechanism of Action of VS-6766 in Recurrent Low-Grade Serous Ovarian CancerPublished: March 19th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5